Matt Powell

[Duke Ob/Gyn @dukeobgyn]

We are beyond grateful to and proud of #gynonc @AngelesSecord for her dedication and commitment to research, education and patient care. This is just one example of how she is an inspiration! @SGO_org @DukeHospital @DukeCancer @dukemed

[IGCS @IGCSociety]

Thanks for sharing! #ASCO2025

[Moffitt Cancer Center @MoffittNews]

Join us in congratulating Karen Lu, MD (@KarenLuMD), Moffitt’s Physician in Chief, as she takes the helm as President of @SGO_org! This opportunity highlights her dedication to advancing gynecologic cancer care, driving innovation and saving lives. 👏🎉

[OncLive.com @OncLive]

Our first interview of the day was with @LDuska of @uvamedicine, who shared key OS and PFS2 data from the second interim analysis of the KEYNOTE-A18 study. Hear a brief preview of her research below, and check out https://t.co/E5LOd0oQIM for more details! @SGO_org #SGOMtg #gynsm

[Nicole D. Fleming MD @nicoleflemingmd]

💥Post-session highlights from Drs. Hanley and McAlpine with updates on opportunistic #salpingectomy in Canada! 🇨🇦 #SGOMtg #SGO2025

[Shannon Westin, MD, MPH, FASCO @ShannonWestin]

#SGOMtg- on the scene with Dr Fiona Simpkins to discuss impact of her work exploring WEE1 inhibition in CCNE1-expressing #ovariancancer
#gyncsm #SGO2025
@nicoleflemingmd @RiosDoriaMD @meddles28

[Moffitt Cancer Center @MoffittNews]

Congratulations to our Physician In Chief, @karenluMD!

[rcoledude @rcoledude]

So excited to see the gentle giant be recognized at #SGO 2025 annual meeting for contributions to the field particularly in rare ovarian tumors. John Farley also faithfully service our country as a colonel in the US military. Congratulations John!
⁦⁦@VaniamGroup⁩

[Anna Fagotti @annafagottimd]

I’m so proud to launch the Italian version of Olivia at #ESGO2025 today! Olivia is a digital support tool for our ovarian cancer patients & their loved ones that guides them through diagnosis & treatment. https://t.co/8wgWyCgjQW

[IGCS @IGCSociety]

We are deeply saddened by the passing of Dr. Giovanni Scambia, a highly respected leader in the gynecologic oncology community and a valued member of IGCS. Dr. Scambia contributed immensely to our society, participating in multiple IGCS Annual Global Meetings as an attendee, faculty member, and program committee member. His dedication, expertise, and kindness touched the lives of many, and his impact on the field will not be forgotten.
Our thoughts are with his family, colleagues, and all who had the privilege of knowing him. He will be greatly missed.

[Matt Powell @matthewapowell]

@HardRockBet Z no s 5

[Matt Powell @matthewapowell]

@AtomicOVO @HardRockBet ..33. Em

[Moffitt Cancer Center @MoffittNews]

Meet Karen Lu, MD (@karenluMD) who joined Moffitt in June 2024 as the physician in chief. She is a nationally recognized physician-scientist who specializes in advancing care for women with ovarian and endometrial cancers.

Learn more: https://t.co/eZwKuLowKC

[IGCS @IGCSociety]

Meet Dr. Nadeem Abu-Rustum (USA), IGCS President Elect!

View the IGCS Board of Directors here: https://t.co/bJNjXPaMiS

[Matt Powell @matthewapowell]

@IGCSociety @LucreciaMojica Great choice!!!

[Matt Powell @matthewapowell]

Assessment of NIH Research on Womens Health | National Academies. Check this out!!! Women’s health research continues to be grossly underfunded and despite NIH efforts has only gotten worse. Call for radical change at the NIH!! https://t.co/W074XeNrr6

[Eloise Chapman-Davis @Ellachapmd]

Fantastic oral presentation by Dr. Oluloro about how we measure equitable access in clinical trials for Black and BrownWomen socialsituation as exclusion???#fixcomorbiditycriteria#letsequalizetheentrycriteria @#sgo2023 #SGOMtg

[Nicole D. Fleming MD @nicoleflemingmd]

An inspirational message @Frumovitz @MDAndersonNews, we applaud your bravery, courage, strength, and passion always 💜 #SGOMtg #FrumoFighters

[Erin Stevens @erinstevensmd]

The menopause session at #SGOmtg is excellent! And it’s a packed house with tons standing in the back. Thank you for recognizing the need for education on this!

[Dr.Monica Avila @MAvilaMD]

TROP-2 #ADC Sacituzumab in phase II EVER trial from China shows impressive ORR of 50%-No CRs unlike Tidvak (Tissue factor ADC) but PR of 50% vs 24% in TV and comparable DOR 9 vs 8mo in TV. Hmmmm... how to choose if these become available globally #SGOMtg #gyncsm